Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.